Cantor Fitzgerald Estimates ITCI FY2025 Earnings

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Intra-Cellular Therapies in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the biopharmaceutical company will post earnings per share of ($0.25) for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Intra-Cellular Therapies’ current full-year earnings is ($0.64) per share.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The business had revenue of $175.40 million during the quarter, compared to the consensus estimate of $172.30 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The business’s quarterly revenue was up 39.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.25) earnings per share.

A number of other research firms have also recently issued reports on ITCI. Piper Sandler restated a “neutral” rating and set a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Baird R W lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. StockNews.com assumed coverage on Intra-Cellular Therapies in a research note on Thursday. They issued a “hold” rating on the stock. Needham & Company LLC reaffirmed a “hold” rating and issued a $100.00 price target on shares of Intra-Cellular Therapies in a research note on Monday, January 13th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $132.00 price objective (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $102.15.

Intra-Cellular Therapies Trading Up 0.5 %

ITCI opened at $127.15 on Wednesday. The stock has a market cap of $13.48 billion, a PE ratio of -146.15 and a beta of 0.70. Intra-Cellular Therapies has a 1 year low of $62.78 and a 1 year high of $128.00. The stock’s 50 day simple moving average is $90.75 and its 200-day simple moving average is $81.70.

Insider Activity

In related news, CEO Sharon Mates sold 51,000 shares of the company’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. This represents a 4.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, President Michael Halstead sold 22,869 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total value of $2,038,085.28. The disclosure for this sale can be found here. 2.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Intra-Cellular Therapies

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. True Wealth Design LLC bought a new stake in shares of Intra-Cellular Therapies in the third quarter worth about $32,000. GAMMA Investing LLC increased its holdings in shares of Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 240 shares in the last quarter. Capital Performance Advisors LLP bought a new stake in shares of Intra-Cellular Therapies in the third quarter worth about $74,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Intra-Cellular Therapies in the third quarter worth about $97,000. Finally, Quarry LP increased its holdings in shares of Intra-Cellular Therapies by 260.0% in the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 1,300 shares in the last quarter. Institutional investors own 92.33% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.